Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings
Exelixis, Inc.'s (NASDAQ:EXEL) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right now compared to the market in the United States, where around half of the companies
Simply Wall StApr 22 09:36 ET
Pheochromocytoma Pipeline Insight Report 2024, Featuring Genentech, Exelixis, Advanced Accelerator Applications, Enterome, FUJIFILM Toyama Chemical, Ipsen, Pfizer and Astex Pharmaceuticals
Yahoo FinanceApr 18 06:03 ET
Institutional Investors in Exelixis, Inc. (NASDAQ:EXEL) Lost 3.8% Last Week but Have Reaped the Benefits of Longer-term Growth
Yahoo FinanceApr 17 10:20 ET
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 16, 2024-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 fin
ExelixisApr 16 00:00 ET
Unusual Options Activity: FYBR, TECK and Others Attract Market Bets, FYBR V/OI Ratio Reaches 169.5
EST Apr 15th Afternoon Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
moomoo NewsApr 15 13:30 ET
Express News | Exelixis Shares Are Trading Lower After Barclays Downgraded the Stock From Overweight to Equal-Weight
Moomoo 24/7Apr 11 10:12 ET
Exelixis Slips as Barclays Downgrades on Lack of Catalysts
Seeking AlphaApr 11 10:10 ET
Express News | Barclays Downgrades Exelixis to Equal-Weight, Maintains Price Target to $25
Moomoo 24/7Apr 11 08:55 ET
Express News | Exelixis Shares Down 1.8% Premarket After Barclays Cuts to Equal Weight From Overweight
Moomoo 24/7Apr 11 07:49 ET
Express News | Exelixis Inc : Barclays Cuts to Equal Weight From Overweight
Moomoo 24/7Apr 11 06:56 ET
Barclays Downgrades Exelixis (EXEL) to a Hold
TipRanksApr 11 03:05 ET
What Analysts Are Saying About Exelixis Stock
In the preceding three months, 4 analysts have released ratings for Exelixis (NASDAQ:EXEL), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates their recen
BenzingaApr 10 13:00 ET
Express News | JMP Securities Reiterates Market Outperform on Exelixis, Maintains $27 Price Target
Moomoo 24/7Apr 10 11:08 ET
Exelixis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/10/2024 14.43% JMP Securities → $27 Reiterates Market Outperform → Market Outperform 02/07/2024 18.67%
BenzingaApr 10 11:07 ET
Buy Rating for Exelixis Amidst Positive Litigation Outlook and Cabozantinib Sales Performance
TipRanksApr 10 00:25 ET
EXEL or REGN: Which Is the Better Value Stock Right Now?
Yahoo FinanceApr 9 11:40 ET
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)
TipRanksApr 8 22:10 ET
Top Buy-rated Stocks and Sell-rated Stocks Within Health Care - Citi
Seeking AlphaApr 4 11:12 ET
Exelixis Insider Lowered Holding By 28% During Last Year
Looking at Exelixis, Inc.'s (NASDAQ:EXEL ) insider transactions over the last year, we can see that insiders were net sellers. That is, there were more number of shares sold by insiders than there wer
Simply Wall StApr 4 09:53 ET
Insiders Are Dumping These 10 Healthcare Stocks
Yahoo FinanceMar 28 08:13 ET
No Data
No Data